UNITED
      STATES


SECURITIES
      AND EXCHANGE COMMISSION


WASHINGTON,
      D.C. 20549





**FORM
      10-KSB**





x
      ANNUAL REPORT PURSUANT
      TO SECTION 13 OR 15(d) OF THE SECURITIES


EXCHANGE
      ACT OF 1934





**For
      the Fiscal Year Ended December 31, 2006**





OR




o
      TRANSITION REPORT
      PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES


EXCHANGE
      ACT OF 1934





For
      the
      transition period from **N/A** to **N/A**


Commission
      File Number: **333-137170**





**Bond
      Laboratories, Inc.**


(Name
      of
      small business issuer as specified in its charter)


**Nevada**
              **20-3464383**State
                  of Incorporation
              IRS
                  Employer Identification No.




**777
      South Highway 101, Suite 215, Solana Beach, CA 92975**


(Address
      of principal executive offices)





Registrant's
      telephone number, including Area Code: **(858)
      847-9000**


Securities
      registered pursuant to Section 12(b) of the Act: None


Securities
      registered pursuant to Section 12(g) of the Act:





**Common
      Stock, $.01 Par Value**





Check
      whether the Registrant (1) has filed all reports required to be filed by Section
      13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months
      (or
      for such shorter period that the Registrant was required to file such reports)
      and (2) has been subject to such filing requirements for the past 90
      days.




YES x NO
o





Check
      if
      disclosure of delinquent filers in response to Item 405 of Regulation S-B is
      not
      contained in this form, and no disclosure will be contained, to the best of
      the
      Registrant's knowledge, in definitive proxy or information statements
      incorporated by reference in Part III of this Form 10-KSB or any amendment
      to
      this Form 10-KSB. x





Registrant’s
      revenues for the most recent fiscal year were $ 9,414





The
      aggregate market value of the common stock held by non-affiliates computed
      based
      on the closing price of such stock on March 15, 2007, was approximately
      $50,000





Transitional
      Small Business Disclosure Format (check one): Yes o No x





Indicate
      by check mark whether the registrant is a shell company (as defined in Rule
      12b-2 of the Exchange Act. Yes o No x







**PART
      I**





**ITEM
      1. DESCRIPTION OF BUSINESS.**





Except
      for historical information contained herein, the following discussion contains
      forward-looking statements that involve risks and uncertainties. Such
      forward-looking statements include, but are not limited to, statements regarding
      future events and the Company’s plans and expectations. Actual results could
      differ materially from those discussed herein. Factors that could cause or
      contribute to such differences include, but are not limited to, those discussed
      elsewhere in this Form 10-KSB or incorporated herein by reference, including
      those set forth in *Management’s
      Discussion and Analysis or Plan of Operation.*





**Overview**




Bond
      Laboratories, Inc. (the "Company” or “Bond Laboratories "), a Nevada corporation
      was formed in July 26, 2005. **** Bond
      Laboratories is building a turn-key Nutraceutical Dietary Supplement business
      focusing on the three major categories of the industry; Energy, Pain Relief
      and
      Weight loss. Utilizing state of the art, alternative delivery methods vs.
      antiquated capsules and pills, Bond Laboratories caters to all five of the
      major
      distribution channels of the nutraceutical dietary supplement
      business.





Management
      believes that consumers of dietary supplements and functional foods have a
      continuing desire for innovative, effective products and the market clearly
      indicates consumer willingness to spend money on value-added products such
      as
      energy drinks, energy bars, and novel functional foods that offer solutions
      to
      health problems. In fact, Datamonitor (DTM.L), London, U.K., has recently
      released a new report entitled “Evolution of Global Consumer Trends,”
identifying ‘Health’ and ‘Convenience’ as 2 of the top 10 global trends
      influencing consumer buying behavior in Europe, North America, Latin American
      and Asia-Pacific.




***Health:*** There is
      a growing recognition that physical and mental wellbeing are influential in
      consumer buying behavior. The report by Datamonitor (DTM.L), London, U.K.
      discloses statistics that show that an overwhelming majority of European and
      U.S. consumers feel that improving their health is important. Even more
      significant is that 64% of Europeans and U.S. consumers actually took "steps"
      to
      improve their health during 2003-04. Datamonitor also identifies the crossover
      trend of health and convenience (health on-the-go) as an under-targeted
      opportunity with high growth potential.




***Convenience:*** There
      exists an increasing demand for easier, faster and disposable products.
      Convenience, time saving products, and “quick fixes” are important to 82% of
      European and U.S. consumers. Convenience is also impacting personal care
      consumption; 57% of European and U.S. consumers report that they groom while
      on-the-move and 58% admit to grooming at-work. Bond Laboratories is ideally
      positioned to leverage the opportunity of providing products to this broad
      consumer base.




Bond
      will
      initially develop proprietary formulated products that address the three largest
      nutraceutical mega-categories; Energy, Pain Relief and Weight-loss and is
      focusing its product development, marketing, and sales initiatives on unique
      marketing subgroups within these mega-categories. An example of such an
      opportunity and the first focus of Bond Laboratories is the exploding energy
      drink market. New product concepts and heavy marketing have driven the global
      energy drinks market into the mainstream. Consumption jumped by 18 per cent
      in
      2004 to 2,410 million liters, according to the new 2005 Global Energy Drinks
      report from specialist drinks consultancy Zenith International with new
      innovations acting as a driving factor in this segment.





The
      concept of caffeine based 'body and mind stimulating' energy drinks originates
      from Japan and Thailand. According to the reports produced by Zenith
      International, although Asia Pacific remains the top producing region, with
      a 58
      per cent share of total volume in 2004, its lead is expected to decline as
      other
      areas develop. North America, for example, has just overtaken Western Europe
      as
      the second largest producer with 15% total volume share.. From small beginnings,
      the energy drink industry has maintained an average growth since 1999 at an
      impressive 68 per cent a year. The United States is expected to become the
      largest national market by 2009.




2





The
      Company has a focused vision, talented executive leadership, excellent product
      innovation capabilities, significant manufacturing experience, and the potential
      to attain success within the functional food marketplace. The executive team
      is
      comprised of experienced businessmen who have been instrumental in creating
      products that have been profitably marketed in the food, drug and mass sectors
      (FDM), multi level marketing sector (MLM), club/warehouse store sector,
      direct-to-consume sector (DTC), contract manufacturing sector, and Rx/OTC
      marketplace sectors. These products were successful in achieving substantially
      higher margins than most other consumer products categories and we believe
      that
      this team will bring the same success and results to Bond Laboratories’
products.





**Competition**





Bond
      Laboratories will encounter competition in each market that they enter. Patent
      applications that cover new embodiments of technology will be pursued wherever
      possible. While the Company cannot assure that the patents and applications
      will
      block competitive products, they should help the Company become a significant
      participant in the marketplace.





The
      industry leader is Red Bull with annual sales of approximately $1 billion.
      The
      other leaders in the category include Monster, (manufactured and distributed
      by
      Hanson Beverages), RockStar, (now distributed by Coca Cola along with its own
      brand ‘Full Throttle’), Amp, (manufactured and distributed by Pepsi) and SoBe,
      (also manufactured and distributed by Pepsi). Recognizing that it would be
      financially impossible to purchase shelf space in grocery stores or 7/11 stores
      on a competitive basis, the Company will be marketing ‘Fusion’ directly to
      college students with an emphasis on new form of delivery, higher quality,
      and
      superior taste.





To
      managements’ knowledge and observation, almost all energy products are sold in
      cans. Fusion is sold as a powder in a convenient vial which is poured into
      cold
      water at the time of consumption. This gives ‘Fusion’ a major advantage that is
      stressed to the consumers in all marketing materials. Not only is it easier
      to
      carry around a small tube or two vs. several cans, (which must stay cold),
      but
      cans use science and technology developed over ten years ago.





Since
      1995, there have been great discoveries in energy producing nutrients. More
      important, studies have clearly demonstrated that most ingredients are not
      stable in normal beverage products and that the longer they stay in contact
      with
      liquid, the less potent they become. These sensitive substances begin to degrade
      and lose strength almost immediately when mixed with liquid at the time of
      production. Shelf life and exposure to light promote further loss of their
      potency, not to mention the negative impact of the interaction with the aluminum
      can produces.





Fusion
      is
      being marketed as the new technology for ‘energy on demand’ to a generation that
      responds very positively to this kind of message. In addition, because Fusion
      is
      in a powder form, its usage is not limited like liquid in a can and can be
      expanded far beyond simple consumption. The product web site; “got-fusion.com”
highlights recipes that include mixing the powder with not only cold water
      as
      expected, but with alternatives such as plain yogurt for breakfast, vanilla
      ice
      cream, lemonade, ice tea, and may also be used as a substitute ingredient for
      baking sugar cookies.




3





**Marketing
      Strategy**





In
      the
      Nutritional Supplement business, it is difficult to bring a new product to
      market and sustain differentiation because the base materials are typically
      available in the public domain. (Patented materials are rarely if ever marketed
      directly by the company that did the development work or sold to an exclusive
      end user.) If a start-up company overcomes the obstacles that typically cause
      failure such as insufficient capital or lack of strong marketing relationships
      to get their product into the hands of the consuming public, they often find
      themselves competing with a major distribution company that have brought their
      own version of the start-up company’s new product to market after the initial
      product launch. Major distribution companies have the advantage of copying
      the
      new start up product at a less expensive retail price because of their ability
      to begin production at cost effective levels.





Not
      only
      will the Company be able to offer a level of research and development expertise
      that would normally be unavailable to entrepreneurs, management also intends
      to
      direct its marketing and distribution through the management’s pre-existing
      relationships. Successful in its initial campaign, (5% - 10% market share),
      Bond
      Laboratories can then capture the contract manufacturing business for the major
      distribution companies that are looking to enter the market with a similar
      product, (90% - 95% market share), and maximize the total potential of a
      products lifecycle vs. just the initial introduction stages.





**Partners
      vs. Representation**





Most
      new
      companies conceive a product idea, test market the product, and then either
      seek
      out a distributor or attempt to directly get retail space. This means that
      the
      brokers who represent and support the new product through the distribution
      channels are not directly involved in the continued development of the product,
      or emotionally invested in the lifecycle of the product. By contrast, Bond
      is
      partnering with well established brokers in each of the five major areas of
      distribution, contracting for their services at market rates and offering equity
      incentives in the company that will vest over the course of the success of
      each
      product’s life. Typically, the product representative opens the difficult door
      for a new product/company, but do not get the opportunity to participate in
      the
      increased overall value and success of the ‘brand’ resulting from their initial
      and ongoing efforts. Management believes that as initial shareholders in the
      Company, these distributors will keep its products at the top of their priority
      list and take every effort to make sure that new ideas and concepts are being
      considered by Bond before anyone else.





**Revenues**





Customers
      are invoiced upon shipment to customers at which time revenue from product
      sales
      is recognized. Units are shipped under the terms of FOB shipping point when
      collectibility is probable. Revenues for services are recognized upon completion
      of the services. For consulting services and other fee-for-service arrangements,
      revenue is recognized upon completion of the services. The Company has adopted
      the Securities and Exchange Commission’s Staff Accounting Bulletin (SAB) No.
      104, which provides guidance on the recognition, presentation and disclosure
      of
      revenue in financial statements. ****





**Additional
      Information**





Bond
      files reports and other materials with the Securities and Exchange Commission.
      These documents may be inspected and copied at the Securities and Exchange
      Commission,  Judiciary
      Plaza, 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You can obtain
      information on the operation of the Public Reference Room by calling the
      Commission at 1-800-SEC-0330. You can also get copies of documents that the
      Company files with the Commission through the Commission’s Internet site at www.sec.gov .




4





**ITEM
      2. DESCRIPTION OF PROPERTY.**




The
      Company operates as a company headquartered in Solana Beach, CA. On May 17,
      2006, the Company signed a one year lease to rent space for $1,570 per month.
      On
      July 3, 2006 the Company entered into a lease for 1,875 sq. ft. of office
      warehouse space in Murrieta, CA. The term of the lease is for two years with
      rent of $1968.75 per month beginning September 1, 2006.





**ITEM
      3. LEGAL PROCEEDINGS**





We
      are
      not a party to any pending material legal proceedings and are not aware of
      any
      threatened or contemplated proceeding by any governmental authority against
      us.





**ITEM
      4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.**





The
      Company submitted no matters to a vote of its security holders during the fiscal
      year ended December 31, 2006.





**PART
      II**





**ITEM
      5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER
      MATTERS.**





Bond
      common stock is traded in the over-the-counter market, and quoted in the
      National Association of Securities Dealers Inter-dealer Quotation System
      (“Electronic Bulletin Board) and can be accessed on the Internet at www.otcbb.com under
      the symbol “Applied for”





At
      December 31, 2006, there were 5,002,000 shares of common stock of Bond that
      were
      issued to approximately 25 of the Company’s common stock shareholders of
      record.





The
      following table sets forth for the periods indicated the high and low bid
      quotations for Bond’s common stock. These quotations represent inter-dealer
      quotations, without adjustment for retail markup, markdown or commission and
      may
      not represent actual transactions.


**FISCAL
                  2006**
              
              **HIGH BID**
              
              **LOW
                  BID**Quarter
                  Ended December 31, 2006
              
              $
              .0
              
              $
              .0Quarter
                  Ended September 30, 2006
              
              
              .0
              
              
              .0Quarter
                  Ended June 30, 2006
              
              
              .0
              
              
              .0Quarter
                  Ended March 31, 2006
              
              
              .0
              
              
              .0
  **FISCAL
                  2005**
              
              **HIGH
                  BID**
              
              **LOW
                  BID**Quarter
                  Ended December 31, 2005
              
              $
              .0
              
              $
              .0Quarter
                  Ended September 30, 2005
              
              
              .0
              
              
              .0
  5


Bond
      has
      never paid dividends on any of its common stock shares. Bond does not anticipate
      paying dividends at any time in the foreseeable future and any profits will
      be
      reinvested in Bond’s business. Bond’s Transfer Agent and Registrar for the
      common stock is Colonial Stock Transfer located in Salt Lake City,
      Utah.





**Sale
      of Unregistered Securities**





Through
      December 31, 2006, the Company has not sold any unregistered
      securities.


**Stock
                  issued for****Stock
                  issued**
              
              
              
              **Stock
                  issued**
              
              **Warrents****Quarter
                    Ended**
              
              **for
                  Cash**
              
              **Cash
                    Received**
              
              **for
                  Services**
              
              **Exercised**September
                  30, 2005December
                  31, 2005
              
              
              
              
              
              
              
              
              
              
              
              -March
                  31, 2006
              
              
              
              
              
              
              
              
              
              
              
              -June
                  30, 2006Total
                  Issued
              
              
              -
              
              
              -
              
              
              -
              
              
              -


**ITEM
      6. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF
      OPERATION**





Management’s
      discussion and analysis contains statements that are forward-looking and involve
      risks and uncertainties. Several factors could cause actual results to differ
      materially from those described in such forward-looking statements. This
      includes the Company’s ability to manage growth, involvement in litigation,
      competition in the health produce industry, ongoing contractual relationships,
      dependence upon key personnel, changes in customer demand for product and
      services, and the adoption of new, or changes in, accounting policies, practices
      and estimates and the application of such policies, practices, and estimates,
      and federal and state governmental regulation, specifically in the areas of
      electronic transaction processing in the health care industries.





The
      following financial data should be read in conjunction with the financial
      statements of Bond and related notes and other financial information appearing
      elsewhere in this report.




**Plan
      of Operations**




We
      were
      incorporated in Nevada in July of 2005. The focus of the company has always
      been
      to develop an alternative nutraceutical dietary supplement delivery platform
      vs.
      antiquated capsules and pills. There are two major trends that lead management
      to believe that an enormous window of opportunity is developing in the
      supplement business that will change consumers’ purchasing habits across the
      board.




First,
      with the constant increase in healthcare, consumers are focusing on prevention
      in greater numbers, to reduce the costs of eventual treatment. This trend has
      increased consumer commitment and consumption of dietary
      supplements.




Second,
      Consumers are living longer, but as they get older, their stomach’s ability to
      process capsules and pills reduces. In fact, delivery of supplements through
      the
      stomach is one of the least effective ways for the body to benefit from the
      ingredients. It is not unusual for 75%+ of the contents to dissipate through
      the
      liver before traveling to the parts of the body it is intended for.




In
      September of 2005, we assembled a core group of individuals with extensive
      backgrounds and experience in the Nutraceutical Supplement business to form
      our
      development team. As we were relying upon limited funds from one of the
      principles and a few individuals investors, our development team was brought
      in
      on a consulting basis which enabled us to maximize our funds by paying for
      only
      time actually used. In exchange, several members of the development team were
      granted founders shares. This strategy kept our initial overhead below $20,000
      per month.




6




It
      was
      concluded early on that the Company should limit its focus to the three largest
      SKU’s in the Supplement business; Energy, Pain Relief and Diet. The Company
      would not focus on commodity products like individual Vitamins as they remain
      a
      very low margin product with vast competitors dominating the space. Of the
      three
      focus categories, it was determined that Energy would be the easiest and least
      expensive product line to introduce first and would enable the Company to
      simultaneously explore the challenges of delivering ingredients through a powder
      vs. traditional capsules and pills.




When
      we
      first began our research, there were over 100 Energy drinks on the market,
      but
      only a handful of powders with two powders dominating the retail market; Zipfizz
      and Rip It (an extension of the Rip It Energy Drink). Zipfizz sold 20 million
      individual serving tubes in 2005. Having determined that the largest groups
      of
      consumers of Energy drinks were between the ages of 18 and 30 with the majority
      of those between 18 and 22, we decided to go target the college markets first.
      From September through December we worked on formulations, branding and
      packaging. The name for the product we selected was Fusion. Three flavors were
      developed, Atomic (a lemon line flavor similar to existing energy drinks on
      the
      market), Sunrise, (a tangerine/orange flavor and Cosmo, (a strawberry
      punch).




In
      January of 2006 we completed our packaging, determined the price pointing,
      and
      contracted with a laboratory in Arizona to manufacture our first production.
      We
      began test marketing in February 2006 at San Diego State University and the
      University of California at San Diego. Cards were handed out on campus that
      invited the students to log onto our web site to receive a free sample box
      of
      Fusion. Approximately 4,000 cards were dispersed that resulted in over 400
      responses, a very high percentage based on the fact that the students actually
      had to hold onto the card until they got home and then log onto the web site
      and
      provide their personal contact information.




From
      inception to test marketing we expended approximately $150,000.




With
      close to a 10% response rate on our ‘Give Away’ cards, we projected that
      approximately 10% of those individuals would become customers and place
      replacement orders. We were quite disappointed when less than 1% followed
      through. We concluded that there were three areas that would account for the
      limited results:




·
            Taste/energy
                level achieved




·
            Price




·
            Distribution
                method




In
      April
      2006, we tested a new distribution model by selling Fusion at a few local street
      fairs. We handed out 2 ounce samples, sold 16 ounce pre-mixed cups and box
      sets
      of 5 tubes, cups and a stirrer. These results were far more positive. At each
      fair, we handed out approximately 2,000 samples, sold approximately 200+ cups
      and about 50 boxes. In each box was a card explaining how to re-order Fusion
      from our web site and several customers have followed through with placing
      new
      orders.




Based
      on
      the April 2006 test marketing results, we revamped our marketing and
      distribution model. Our target consumer became adults between the ages of 25
      and
      60. It was also determined that a distribution network in needed to be developed
      prior to bringing the product to market and that we must take control of our
      own
      production. To accomplish the first of these steps, we decided to offer equity
      to certain groups that had distribution relationships in the retail outlets
      that
      cater to our newly defined target market. They vest into their ownership based
      on their success. We have not asked them to discount their
      services.




In
      furtherance of our second goal, in July 2006, we signed a lease for a 1,850
      sq.
      ft. warehouse in Murrieta, CA. Blending and packaging equipment orders were
      placed with November 2006 delivery dates. By the end of November, we anticipated
      having the warehouse to be a fully functional R&D/Manufacturing/Production
      lab. Proto-type packaging is being developed simultaneously. The combined cost
      of the equipment, raw materials and packaging equipment will be $150,000. By
      taking control of our own production will reduce our cost of goods sold by
      close
      to 30%.




7




Our
      sales
      to date have been limited to street fairs and internet orders. Although
      insignificant in size, these sales have enabled us to identify our true target
      customer for the product and attract interest from several potential
      distributors. More important, these distributors do not currently have Energy,
      Pain Relief or Diet product lines, but do have very positive relationships
      with
      their customer bases. Therefore, they are able to extend the product offering
      and the Company rides on the distributors positive reputations and
      relationships.




We
      are
      dependent upon funding from certain stockholders to sustain our operations.
      As
      of December 31, 2006, we owed these stockholders approximately $430,000. These
      stockholders are under no obligation to continue to provide funding to us.
      These
      stockholders have provided oral assurances that they will continue funding
      our
      operations up to an additional $375,000, however, there are no legally binding
      assurance that they will continue funding us in the near-term or that the
      amount, timing and duration of funding from these stockholders will be adequate
      to sustain our operations. Our only outstanding debt aside for these loans
      is
      the accrued salary and expenses of our President which totaled $200,000 as
      of
      December 31, 2006. None of the proceeds from this offering will be used to
      pay
      back any loans and our President has agreed to leave his unpaid salary and
      expenses on the books until we have raised a minimum of $1 million. Our current
      cash balance will not be sufficient to repay the obligations as they are
      currently recognized.




Our
      budget through the year 2007 does not rely on proceeds from this offering,
      or on
      any funds received through exercise of our warrants. However, it does assume
      that the $375,000 committed from existing shareholders is received. All new
      capital inflows will enable us to accelerate our product development, market
      testing, and will provide us with an opportunity to commence contract
      manufacturing ahead of schedule and to expand our avenues of product candidates.




Completion
      of these projects, as well as our ability to satisfy our operational and
      overhead expense requirements beyond 2006, is dependent on our raising
      additional capital. Should we fail to generate sufficient cash inflows either
      from operations or through future equity or debt sales, we may not be able
      to
      implement our business plan, complete any of these projects, or sustain our
      operations through the second quarter of 2007.




Further
      product development and fulfillment of the distribution channels we are planning
      to pursue will require us to use the funds received through this offering.
      To
      fulfill our strategic goals, the research and product development and full
      production costs will total approximately $2,000,000.




As
      discussed in our risk factors, our business operates in a highly competitive
      environment. Continued economic slowdown as a result of terrorist attacks,
      market decline, the war in Iraq, or a combination thereof appears to have
      resulted in a general reduction of external capital available to start-up
      nutraceutical companies. In addition, new products or delivery platforms could
      be developed which could compete directly with our product candidates,
      significantly reducing our potential revenue stream.





*Overhead
                Costs.*The Company estimates that our overhead costs over the next two years
                will
                amount to approximately three million dollars, categorized as
                follows:




·
            
            Approximately
                $1,100,000 for laboratory rent, equipment, maintenance and materials;




·
            
            Approximately
                $900,000 for administrative expenses including salaries, office rent
                and
                maintenance;




8




·
            
            Approximately
                $1,000,000 in marketing, legal and other expenses, including trademark
                filling fees, financing costs and professional fees.





The
      following financial data should be read in conjunction with the financial
      statements of Bond and related notes and other financial information appearing
      elsewhere in this report.


Statement
                  of Operations Data
              
              
              
              
              
              For
                  periodsYears
                  Ended
                Decemer
                  31,
              
              Years
                  Ended
                December
                  31,
              
              May
                  1, 2005to
                  December
                    31,2006
              
              2005
              
              2006Revenues
              
              $
              9,414
              
              $
              -
              
              $
              9,414Cost
                  of Goods Sold
              
              
              8,318
              
              
              -
              
              
              8,318Operating
                  and Other Expenses
              
              
              649,091
              
              
              165,305
              
              
              814,396Net
                  Loss
              
              $
              (647,995
              )
              $
              (165,305
              )
              $
              (813,301
              )Balance
                  Sheet Data:Years
                  Ended Decemer 31,
              
              
              Years
                  Ended December 31,2006
              
              
              2005Current
                  Assets
              
              $
              60,753
              
              $
              35,309Total
                  Assets
              
              
              125,317
              
              
              35,309Current
                  Liabilities
              
              
              229,500
              
              
              84,081Non
                  Current Liabilities
              
              
              611,289
              
              
              116,513Total
                  Liabilities
              
              
              840,789
              
              
              200,594Working
                  Capital (Deficit)
              
              
              (168,747
              )
              
              (48,772
              )Shareholders'Equity
                  (Deficit)
              
              $
              (715,473
              )
              $
              (165,285
              )


The
      Company has declared no common stock dividends since its inception.




**Results
      of operations**





***Fiscal
      Year End December 31, 2006, Compared to Fiscal Year End December 31,
      2005***




We
      are a
      development stage company and have generated limited revenues from sales of
      our
      first product, Fusion. For the years ended December 31, 2006 we generated
      $9,414. No sales were generated in 2005. Our future revenue plan is uncertain
      and is dependent on our ability to effectively introduce our products to our
      target consumers, generate sales, and obtain contract manufacturing
      opportunities. The margin for nutraceutical supplement products depends on
      the
      distribution market. In warehouse clubs, the wholesale margin is less than
      30%.
      In Mass retail marekts which include grocery and convenience stores, the margins
      are 40%+. In MLM, (Multi-level Marketing), and Direct to Consumer markets,
      the
      margins are 50%+. Margins for Contract Manufacturing are 20-30%.




The
      Company incurred losses of approximately $650,187, and $165,304 for the year
      ended December 31, 2006 and 2005, respectively. Our losses since our inception
      through December 31, 2006 amount to $815,493. The increase in the loss from
      2005
      to 2006 reflects our investment in product development, packaging, contract
      manufacturing and marketing. Once our warehouse is fully functional and we
      retain a marketing director, our monthly operating expenses are expected to
      grow
      to $75,000.




9




**Liquidity
      and Capital Resources**




The
      Company has maintained a minimum of three months of working capital in the
      bank
      since September of 2005. This reserve was intended to allow for an adequate
      amount of time to secure additional funds from investors as needed. To date,
      the
      Company has succeeded in securing capital as needed, but there is no guarantee
      this will continue. As of December, 2006, the required amount was approximately
      $60,000, ($20,000 per month with the President accruing his salary). The company
      had a balance of $60,753 in its bank account at the end of December, 2006.
      Because the Company continues to rely upon private investors for additional
      capital to grow the business, it can not and will not accept trade credit from
      any vendors. All significant purchases are pre-paid or a 50% deposit is made
      with the balance available in the bank account.




We
      believe we will have to rely on public and private equity and debt financings
      to
      fund our liquidity requirements over the intermediate term. We may be unable
      to
      obtain any additional financings on terms favorable to us, or obtain additional
      funding at all. If adequate funds are not available on acceptable terms, and
      if
      cash and cash equivalents together with any income generated from operations
      fall short of our liquidity requirements, we may be unable to sustain
      operations. Continued negative cash flows could create substantial doubt
      regarding our ability to fully implement our business plan and could render
      us
      unable to expand our operations, successfully promote our brand, develop our
      products, respond to competitive pressures, or take advantage of acquisition
      opportunities, any of which may have a material adverse effect on our business.
      If we raise additional funds through the issuance of equity securities, our
      stockholders may experience dilution of their ownership interest, and the newly
      issued securities may have rights superior to those of our common stock. If
      we
      raise additional funds by issuing debt, we may be subject to limitations on
      our
      operations, including limitations on the payments of dividends





**Other
      Considerations**





There
      are
      numerous factors that affect the business and the results of its operations.
      Sources of these factors include general economic and business conditions,
      federal and state regulation of business activities, the level of demand for
      product services, the level and intensity of competition in the health drink
      industry, and the ability to develop new services based on new or evolving
      technology and the market's acceptance of those new services, the Company’s
      ability to timely and effectively manage periodic product transitions, the
      services, customer and geographic sales mix for any particular period, and
      our
      ability to continue to improve our infrastructure including personnel and
      systems to keep pace with the Company’s anticipated rapid growth.





10





**ITEM
      7. FINANCIAL STATEMENTS**





**BOND
      LABORATORIES, INC.**


**TABLE
        OF CONTENTS**
  **Page**INDEPENDENT
                  REGISTERED PUBLIC ACCOUNTING FIRM:
              
              F-2Jewett,
                  Schwartz, Wolfe & AssociatesCONSOLIDATED
                  FINANCIAL STATEMENTS:Balance
                  Sheet at December 31, 2006
              
              F-3Statements
                  of Operations for the years ended December 31, 2006 and
                  2005
              
              F-4And
                  for period from July 25, 2005 (inception) to December 31,
                  2006Statements
                  of Stockholders’ Equity for the years ended December 31, 2006 and
                  2005
              
              F-6And
                  for period from July 25, 2005 (inception) to December 31,
                  2006Statements
                  of Cash Flows for the years ended December 31, 2006 and
                  2005
              
              F-5And
                  for period from July 25, 2005 (inception) to December 31,
                  2006NOTES
                  TO FINANCIAL STATEMENTS
              
              F-7





F-1




REPORT
      OF
      INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM




To
      the
      board of directors and shareholders of


Bond
      Laboratories, Inc.





We
      have
      audited the accompanying balance sheet of Bond Laboratories, Inc. (A Development
      Stage Company) as of December 31, 2006 and the related statements of operations,
      changes in shareholders' deficit and cash flows for the year ended December
      31,
      2006 and 2005 and for period from July 26, 2005 (inception) through December
      31,
      2006. These financial statements are the responsibility of the Company's
      management. Our responsibility is to express an opinion on these financial
      statements based on our audits.





We
      conducted our audits in accordance with the standards of the Public Company
      Accounting Oversight Board (United States). Those standards require that we
      plan
      and perform the audits to obtain reasonable assurance about whether the
      financial statements are free of material misstatement. An audit includes
      examining, on a test basis, evidence supporting the amounts and disclosures
      in
      the financial statements. An audit also includes assessing the accounting
      principles used and significant estimates made by management, as well as
      evaluating the overall financial statement presentation. We believe that our
      audits provide a reasonable basis for our opinion.





In
      our
      opinion, the financial statements referred to above present fairly, in all
      material respects, the financial position of Bond Laboratories, Inc. (A
      Development Stage Company) as of December 31, 2006 and the results of its
      operations and its cash flows for the periods ended December 31 2006 and 2005,
      and from July 26, 2005 (inception) through December 31, 2006 in conformity
      with
      accounting principles generally accepted in the United States of
      America.





These
      financial statements have been prepared assuming that the Company will continue
      as a going concern. As discussed in Note 2 to the financial statements, the
      Company has operating and liquidity concerns, has incurred in net losses
      approximating $815,000 during the period July 26, 2005 (inception) through
      December 31, 2006. These factors raise substantial doubt about the ability
      of
      the Company to continue as a going concern. The financial statements do not
      include any adjustments that might result from the outcome of these
      uncertainties. In this regard, Management is proposing to raise any necessary
      additional funds through loans and additional sales of its common stock. There
      is no assurance that the Company will be successful in raising additional
      capital.





As
      further discussed in Note 11 to the financial statements, management has
      restated their financial statements in consideration of certain errors
      identified in the financial statements previously issued for 2005. The result
      of
      the restatement had no effect on the previously issued independent registered
      public accountants’ report on these financial statements.





*/s/
      Jewett, Schwartz, Wolfe & Associates*





Hollywood,
      Florida


March
      27,
      2007





F-2


**BOND
                LABORATORIES, INC.****BALANCE
                SHEET****Development
                Stage Company**




**December
                31, 2006**ASSETSCURRENT
                ASSETSCash
            
            $
            60,753Total
                current assets
            
            
            60,753Fixed
                assets - net
            
            
            64,564TOTAL
                ASSETS
            
            $
            125,317LIABILITIES
                AND STOCKHOLDERS' EQUITY:CURRENT
                LIABILITIES:Accounts
                payable
            
            $
            14,500Accrued
                liabilities
            
            
            215,000Accrued
                interest
            
            
            13,996Total
                current liabilities
            
            
            243,496Loans
                payable - related party
            
            
            117,294Convertible
                notes payable
            
            
            480,000Total
                liabilities
            
            
            840,790STOCKHOLDERS'
                DEFICIT:Preferred
                stock, $.01 par value, 10,000,000 shares authorized;5,000,000
                issued and outstanding
            
            
            50,000Common
                stock, $.01 par value, 75,000,000 shares authorized;4,952,000
                issued and outstanding
            
            
            49,540Additional
                paid in capital
            
            
            -Accumulated
                deficit
            
            
            (815,013
            )Total
                stockholders' deficit
            
            
            (715,473
            )TOTAL
                LIABILITIES AND STOCKHOLDERS' DEFICIT
            
            $
            125,317The
                accompanying notes are an integral part of these financial
                statements





F-3





**BOND
                LABORATORIES, INC.****STATEMENTS
                OF OPERATIONS****DEVELOPMENT
                STAGE COMPANY****FOR
                THE YEAR ENDED DECEMBER 31, 2006 AND DECEMBER 31,
                2005****AND
                FOR THE PERIOD FROM JULY 26, 2005 (INCEPTION) TO DECEMBER 31,
                2006**




**For
                the Period****from
                JULY 26, 2005****(restated)**
            
            **(inception)
                to December 31,****2006**
            
            **2005**
            
            **2006**REVENUES:Revenue
            
            $
            9,414
            
            $
            -
            
            $
            9,414Total
            
            
            9,414
            
            
            -
            
            
            9,414Cost
                of Goods Sold
            
            
            8,318
            
            
            -
            
            
            8,318Gross
                Profits
            
            
            1,096
            
            
            -
            
            
            1,096OPERATING
                EXPENSES:General
                and administrative
            
            
            509,251
            
            
            144,033
            
            
            653,284Selling
                and marketing
            
            
            37,000
            
            
            7,086
            
            
            44,086Depreciation
                and amortization
            
            
            1,575
            
            
            -
            
            
            1,575Research
                and development
            
            
            82,454
            
            
            11,923
            
            
            94,377Total
                operating expenses
            
            
            630,280
            
            
            163,042
            
            
            793,322OPERATING
                LOSS
            
            
            (629,184
            )
            
            (163,042
            )
            
            (792,226
            )OTHER
                (INCOME) AND EXPENSESInterest
                expense
            
            
            22,296
            
            
            2,263
            
            
            24,559Interest
                income
            
            
            (1,772
            )
            
            -
            
            
            (1,772
            )Total
                other expense
            
            
            20,524
            
            
            2,263
            
            
            22,787INCOME
                TAX (BENEFIT) PROVISION
            
            
            -
            
            
            -
            
            
            -NET
                LOSS
            
            $
            (649,708
            )
            $
            (165,305
            )
            $
            (815,013
            )NET
                LOSS PER SHARE:Weighted
                avergare shares outstanding - basic and diluted
            
            
            1,657,189
            
            
            2,000Loss
                per share - basic and diluted
            
            $
            (0.39
            )
            $
            (82.65
            )The
                accompanying notes are an integral part of these financial
                statements




F-4





**BOND
                LABORATORIES, INC.****STATEMENTS
                OF CASH FLOWS****DEVELOPMENT
                STAGE COMPANY****FOR
                THE YEARS ENDED DECEMBER 31, 2006 AND 2005****AND
                FOR THE PERIOD FROM JULY 26, 2005 (INCEPTION) TO DECEMBER 31,
                2006**




**For
                the Period****from
                July 26, 2005****(restated)**
            
            **(inception)
                to**
              **December
                31,****2006**
            
            **2005**
            
            **2006**CASH
                FLOWS FROM OPERATING ACTIVITIES:Net
                (loss)
            
            $
            (649,708
            )
            $
            (165,305
            )
            $
            (815,013
            )Adjustments
                to reconcile net income to net cash(used
                in) operating activities:Depreciation
                and amortization
            
            
            1,575
            
            
            -
            
            
            1,575Stock
                issued for compensation
            
            
            99,520
            
            
            -
            
            
            99,520Changes
                in assets and liabilities:Accrued
                liabilities
            
            
            135,000
            
            
            80,000
            
            
            215,000Accounts
                payable
            
            
            10,420
            
            
            4,081
            
            
            14,501Accrued
                interest
            
            
            13,996
            
            
            -
            
            
            13,996Net
                cash used in operating activities
            
            
            (389,197
            )
            
            (81,224
            )
            
            (470,421
            )CASH
                FLOWS FROM INVESTING ACTIVITIES:Purchase
                of Intangible Asset
            
            
            (66,139
            )
            
            -
            
            
            (66,139
            )Net
                cash used in investing activities
            
            
            (66,139
            )
            
            -
            
            
            (66,139
            )CASH
                FLOWS FROM FINANCING ACTIVITIES:Purchase
                of common stock
            
            
            -
            
            
            20
            
            
            20Proceeds
                from convertible notes payables
            
            
            480,000
            
            
            -
            
            
            480,000Loans
                from affiliates
            
            
            780
            
            
            116,513
            
            
            117,293Net
                cash provided by financing activities
            
            
            480,780
            
            
            116,533
            
            
            597,313-INCREASE
                IN CASH
            
            
            25,444
            
            
            35,309
            
            
            60,753CASH,
                BEGINNING OF YEAR
            
            
            35,309
            
            
            -
            
            
            -CASH,
                END OF YEAR
            
            $
            60,753
            
            $
            35,309
            
            $
            60,753The
                accompanying notes are an integral part of these financial
                statements




F-5




**BOND
                LABORATORIES, INC.****STATEMENTS
                OF STOCKHOLDERS’ DEFICIT****DEVELOPMENT
                STAGE COMPANY****FOR
                THE YEARS ENDED DECEMBER 31, 2006 AND 2005****AND
                FOR THE PERIOD FROM JULY 26, 2005 (INCEPTION) TO DECEMBER 31,
                2006**




**Common
                Stock**
            
            **Preferred
                Stock**
            
            **Additional**
              **Paid
                in**
            
            **Accumulated****Shares**
            
            **Amount**
            
            **Shares**
            
            **Amount**
            
            **Capital**
            
            **Deficit**
            
            
            **Total****Stock
                Issued July 26, 2005**
            
            
            2,000
            
            $
            20.00
            
            
            -
            
            $
            -
            
            $
            -
            
            $
            -
            
            
            $
            20Net
                loss
            
            
            -
            
            
            -
            
            
            -
            
            
            -
            
            
            -
            
            
            (165,305
            )
            
            
            (165,305
            )**Balance
                as of December 31, 2005**
            
            
            **2,000**
            
            **$**
            **20.00**
            
            
            **-**
            
            **$**
            **-**
            
            **$**
            **-**
            
            **$**
            **(165,305**
            **)**
            
            **$**
            **(165,285**
            **)**Common
                stock issued for compensation
            
            
            4,952,000
            
            
            49,520
            
            
            -
            
            
            -
            
            
            -
            
            
            -
            
            
            
            49,520Preferred
                stock issued for compensation
            
            
            -
            
            
            -
            
            
            5,000,000
            
            
            50,000
            
            
            -
            
            
            -
            
            
            
            50,000Net
                loss
            
            
            -
            
            
            -
            
            
            -
            
            
            -
            
            
            -
            
            
            (649,708
            )
            
            
            (649,708
            )**Balance
                as of December 31, 2006**
            
            
            **4,954,000**
            
            **$**
            **49,540**
            
            
            **5,000,000**
            
            **$**
            **50,000**
            
            **$**
            **-**
            
            **$**
            **(815,013**
            **)**
            
            **$**
            **(715,473**
            **)**The
                accompanying notes are an integral part of these financial
                statements





F-6


BOND
      LABORATORIES, INC.


(A
      Development Stage Company)


NOTES
      TO
      FINANCIAL STATEMENTS


FOR
      THE
      YEARS ENDED DECEMBER 31, 2006


AND
      FOR
      PERIOD FROM JULY 26, 2005 (INCEPTION) TO DECEMBER 31, 2006





NOTE
      1 -
      BACKGROUND




Bond
      Laboratories, Inc. (A Development Stage Company) was incorporated in the state
      of Nevada on July 26, 2005. The Company is a development stage company. The
      Company has started research and development of energy drinks. The Company
      has
      not begun the process of operating this business and is still in the process
      of
      research the best formula for market production.





Bond
      Laboratories is building a Nutraceutical Dietary Supplement business catering
      to
      all five of the distribution segments focusing on the three major categories
      of
      the industry; Energy, Pain Relief and Weight loss, utilizing a state of the
      art,
      alternative delivery method vs. antiquated capsules and pills.





NOTE
      2 -
      GOING CONCERN





The
      accompanying financial statements have been prepared in conformity with
      accounting principles generally accepted in the United States of America which
      contemplate continuation of the Company as a going concern. However, the Company
      has year end losses from operations and had minimal revenues from operations
      in
      2006. During the period July 26, 2005 through December 31, 2006 the Company
      incurred net loss of $649,708. Further, the Company has inadequate working
      capital to maintain or develop its operations, and is dependent upon funds
      from
      private investors and the support of certain stockholders.





These
      factors raise substantial doubt about the ability of the Company to continue
      as
      a going concern. The financial statements do not include any adjustments that
      might result from the outcome of these uncertainties. In this regard, Management
      is proposing to raise any necessary additional funds through loans and
      additional sales of its common stock. There is no assurance that the Company
      will be successful in raising additional capital.




NOTE
      3 -
      SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES





The
      Company prepares its financial statements in accordance with accounting
      principles generally accepted in the United States of America. Significant
      accounting policies are as follows:





Use
      of
      Estimates





The
      preparation of financial statements in conformity with accounting principles
      generally accepted in the United States of America requires management to make
      estimates and assumptions that affect the reported amounts of assets and
      liabilities and disclosure of contingent assets and liabilities at the date
      of
      the financial statements. These estimates and assumptions also affect the
      reported amounts of revenues, costs and expenses during the reporting period.
      Management evaluates these estimates and assumptions on a regular basis. Actual
      results could differ from those estimates.





F-7





BOND
      LABORATORIES, INC.


(A
      Development Stage Company)


NOTES
      TO
      FINANCIAL STATEMENTS


FOR
      THE
      YEARS ENDED DECEMBER 31, 2006


AND
      FOR
      PERIOD FROM JULY 26, 2005 (INCEPTION) TO DECEMBER 31, 2006





NOTE
        3 -
        SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued
 
 Revenue
        Recognition
 
 The
        Company recognizes product revenue in accordance with Staff Accounting Bulletin
        (SAB) No. 104, “Revenue Recognition in Financial Statement” which established
        that revenue can be recognized when persuasive evidence of an
        arrangement exists, the product has been shipped, all significant contractual
        obligations have been satisfied and collection is reasonably assured.





Advertising
      Costs





All
      advertising costs are charged to expense as incurred. Advertising expense for
      the year ended December 31, 2006 was approximately
      $600.





Cash
      and Cash Equivalents





The
      Company considers all highly liquid investments with an original maturity of
      three months or less to be cash equivalents. At December 31, 2006, cash and
      cash
      equivalents include cash on hand and cash in the bank.





Property
      and Equipment





Property
      and equipment is recorded at cost and depreciated over the estimated useful
      lives of the assets using principally the straight-line method. When items
      are
      retired or otherwise disposed of, income is charged or credited for the
      difference between net book value and proceeds realized thereon. Ordinary
      maintenance and repairs are charged to expense as incurred, and replacements
      and
      betterments are capitalized. The range of estimated useful lives used to
      calculated depreciation for principal items of property and equipment are as
      follow:




Asset
                Category
            
            Depreciation/
                Amortization PeriodFurniture
                and Fixture
            
            3
                YearsOffice
                equipment
            
            3
                YearsLeasehold
                improvements
            
            5
                Years




F-8


BOND
        LABORATORIES, INC.
 (A
        Development Stage Company)
 NOTES
        TO
        FINANCIAL STATEMENTS
 FOR
        THE
        YEARS ENDED DECEMBER 31, 2006
 AND
        FOR
        PERIOD FROM JULY 26, 2005 (INCEPTION) TO DECEMBER 31, 2006


NOTE
      3 -
      SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued





Research
      and Development





Costs
      are
      expensed as incurred. Research and Development expense for the year ended
      December 31, 2006 was $82,454.





Income
      Taxes





Deferred
      income taxes are provided based on the provisions of SFAS No. 109, "Accounting
      for Income Taxes" ("SFAS 109"), to reflect the tax effect of differences in
      the
      recognition of revenues and expenses between financial reporting and income
      tax
      purposes based on the enacted tax laws in effect at December 31,
      2006.





Earnings
      Per Share





Basic
      earnings per share is computed by dividing net income (loss) available to common
      shareholders by the weighted average number of common shares outstanding during
      the reporting period. Diluted earnings per share reflects the potential dilution
      that could occur if stock options and other commitments to issue common stock
      were exercised
      or equity awards vest resulting in the issuance of common stock that could
      share
      in the earnings of the Company. As of December 31, 2006, there were no potential
      dilutive instruments that could result in share dilution.





Fair
      Value of Financial Instruments




The
      fair
      value of a financial instrument is the amount at which the instrument could
      be
      exchanged in a current transaction between willing parties other than in a
      forced sale or liquidation.




The
      carrying amounts of the Company’s financial instruments, including cash,
      accounts payable and accrued liabilities, income tax payable and related party
      payable approximate fair value due to their most maturities.




F-9


BOND
        LABORATORIES, INC.
 (A
        Development Stage Company)
 NOTES
        TO
        FINANCIAL STATEMENTS
 FOR
        THE
        YEARS ENDED DECEMBER 31, 2006
 AND
        FOR
        PERIOD FROM JULY 26, 2005 (INCEPTION) TO DECEMBER 31, 2006




NOTE
      3 -
      SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued





Recent
      Accounting Pronouncements




Recent
      accounting pronouncements that the Company has adopted or will be required
      to
      adopt in the future are summarized below.




In
      May
      2005, the Financial Accounting Standards Board (FASB) issued SFAS No. 154,
      "Accounting Changes and Error Corrections" (SFAS 154), which replaces Accounting
      Principles Board (APB) Opinion No. 20, "Accounting Changes," and SFAS No. 3,
      "Reporting Accounting Changes in Interim Financial Statements - An Amendment
      of
      APB Opinion No. 28." SFAS 154 provides guidance on the accounting for and
      reporting of accounting changes and error corrections, and it establishes
      retrospective application, or the latest practicable date, as the required
      method for reporting a change in accounting principle and the reporting of
      a
      correction of an error. SFAS 154 is effective for accounting changes and
      corrections of errors made in fiscal years beginning after December 15, 2005.
      The Company will adopt SFAS 154 in the first quarter of fiscal year 2007 and
      does not expect it to have a material impact on its consolidated results of
      operations and financial condition.





In
      September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements" (SFAS
      157). SFAS 157 provides guidance for using fair value to measure assets and
      liabilities. SFAS 157 addresses the requests from investors for expanded
      disclosure about the extent to which companies measure assets and liabilities
      at
      fair value, the information used to measure fair value and the effect of fair
      value measurements on earnings. SFAS 157 applies whenever other standards
      require (or permit) assets or liabilities to be measured at fair value, and
      does
      not expand the use of fair value in any new circumstances. SFAS 157 is effective
      for financial statements issued for fiscal years beginning after November 15,
      2007 and will be adopted by the Company in the first quarter of fiscal year
      2009. The Company is unable at this time to determine the effect that its
      adoption of SFAS 157 will have on its consolidated results of operations and
      financial condition.





In
      July
      2006, the FASB issued FASB Interpretation No. 48, "Accounting for Uncertainty
      in
      Income Taxes, an interpretation of FASB Statement No. 109" (FIN 48). FIN 48
      clarifies the accounting for uncertainty in income taxes by prescribing the
      recognition threshold a tax position is required to meet before being recognized
      in the financial statements. It also provides guidance on derecognition,
      classification, interest and penalties, accounting in interim periods,
      disclosure and transition. The cumulative effects, if any, of applying FIN
      48
      will be recorded as an adjustment to retained earnings as of the beginning
      of
      the period of adoption. FIN 48 is effective for fiscal years beginning after
      December 15, 2006, and the Company is required to adopt it in the first quarter
      of fiscal year 2008. The Company is currently evaluating the effect that the
      adoption of FIN 48 will have on its consolidated results of operations and
      financial condition and is not currently in a position to determine such
      effects, if any.




F-10




BOND
        LABORATORIES, INC.
 (A
        Development Stage Company)
 NOTES
        TO
        FINANCIAL STATEMENTS
 FOR
        THE
        YEARS ENDED DECEMBER 31, 2006
 AND
        FOR
        PERIOD FROM JULY 26, 2005 (INCEPTION) TO DECEMBER 31, 2006


NOTE
      3 -
      SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued





Recent
      Accounting Pronouncements





In
      June
      2006, the FASB ratified Emerging Issues Task Force (EITF) Issue No. 06−3 (EITF
      06-3), “How Taxes Collected from Customers and Remitted to Governmental
      Authorities Should Be Presented in the Income Statement (That Is, Gross versus
      Net Presentation).” EITF 06−3 applies to any tax assessed by a governmental
      authority that is directly imposed on a revenue producing transaction between
      a
      seller and a customer. EITF 06−3 allows companies to present taxes either gross
      within revenue and expense or net. If taxes subject to this issue are
      significant, a company is required to disclose its accounting policy for
      presenting taxes and the amount of such taxes that are recognized on a gross
      basis. The Company currently presents such taxes net. EITF 06−3 is required to
      be adopted during the first quarter of fiscal year 2008. These taxes are
      currently not material to the Company’s consolidated financial
      statements.





In
      September 2006, the SEC issued Staff Accounting Bulletin No. 108, "Considering
      the Effects of Prior Year Misstatements when Quantifying Misstatements in
      Current Year Financial Statements" (SAB 108). SAB 108 provides guidance on
      the
      consideration of the effects of prior year misstatements in quantifying current
      year misstatements for the purpose of a materiality assessment. SAB 108
      establishes an approach that requires quantification of financial statement
      errors based on the effects of each on a company's balance sheet and statement
      of operations and the related financial statement disclosures. Early application
      of the guidance in SAB 108 is encouraged in any report for an interim period
      of
      the first fiscal year ending after November 15, 2006, and will be adopted by
      the
      Company in the first quarter of fiscal year 2007. The Company does not expect
      the adoption of SAB 108 to have a material impact on its consolidated results
      of
      operations and financial condition.





FSP
      FAS
      123(R)-5 was issued on October 10, 2006. The FSP provides that instruments
      that
      were originally issued as employee compensation and then modified, and that
      modification is made to the terms of the instrument solely to reflect an equity
      restructuring that occurs when the holders are no longer employees, then no
      change in the recognition or the measurement (due to a change in classification)
      of those instruments will result if both of the following conditions are met:
      (a). There is no increase in fair value of the award (or the ratio of intrinsic
      value to the exercise price of the award is preserved, that is, the holder
      is
      made whole), or the antidilution provision is not added to the terms of the
      award in contemplation of an equity restructuring; and (b). All holders of
      the
      same class of equity instruments (for example, stock options) are treated in
      the
      same manner. The provisions in this FSP shall be applied in the first reporting
      period beginning after the date the FSP is posted to the FASB website. The
      Company does not expect the adoption of FSP FAS 123(R)-5 to have a material
      impact on its consolidated results of operations and financial
      condition.





F-11




BOND
      LABORATORIES, INC.


(A
      Development Stage Company)


NOTES
      TO
      FINANCIAL STATEMENTS


FOR
      THE
      YEARS ENDED DECEMBER 31, 2006


AND
      FOR
      PERIOD FROM JULY 26, 2005 (INCEPTION) TO DECEMBER 31, 2006





NOTE
      4 -
      NOTES PAYABLES





Notes
      payable at December 31, 2006 comprise the following:




December
                31, 2006Convertible
                note payable to individual. The note bears interest at 6% per annum
                and is
                payable at the time of conversion. The note is convertible to common
                stock
                at 50% of the initial public offering price. The notes mature on
                August 1,
                2008
            
            $
            493,996Note
                payable to Small World Traders. Is a revolving loan commitment up
                to
                $250,000 and is due and payable on December 31, 2006. Collateralized
                by
                all the assets of the Company. Original principal balance of $60,000.
                The
                note bears interest at 8% per annum and requires no monthly principal
                and
                interest payments. The Company has accrued all interest due through
                December 31, 2006.
            
            
            117,294Totals
            
            $
            611,290




NOTE
      5 -
      PROPERTY AND EQUIPMENT





Property
      and equipment is summarized as follow at December 31,




2006Equipment
            
            $
            66,139Accumulated
                depreciation
            
            
            (1,575
            )Net
                fixed assets
            
            $
            64,564





Depreciation
      expense for the year ended December 31, 2006 was $1,575.





NOTE
      6 -
      SHARE CAPITAL





On
      July
      26, 2005, the Company authorized 2,000 shares of common stock, at $.01 par
      value
      and 2,000 shares were issued to its shareholder. The Company issued 5,000,000
      to
      preferred stock and 4,952,000 in common stock on August 31, 2006 for $.01 per
      share.





F-12




BOND
      LABORATORIES, INC.


(A
      Development Stage Company)


NOTES
      TO
      FINANCIAL STATEMENTS


FOR
      THE
      YEARS ENDED DECEMBER 31, 2006


AND
      FOR
      PERIOD FROM JULY 26, 2005 (INCEPTION) TO DECEMBER 31, 2006





NOTE
      7 -
      INCOME TAXES





The
      provision (benefit) for income taxes from continued operations for the years
      ended December 31, 2006 and 2005 consist of the following:





2006
            
            2005Current:Federal
            
            $
            -
            
            
            -Deferred:Federal
            
            
            (220,000
            )
            
            (61,500
            )Increase
                in valuation allowance
            
            
            220,000
            
            
            61,500Benefit
                for income taxes, net
            
            $
            -
            
            
            -




The
      difference between income tax expense computed by applying the federal statutory
      corporate tax rate and actual income tax expense is as follows:





December
                31,2006
                and 2005Statutory
                federal income tax rate
            
            
            35.0
            %Increase
                in valuation allowance
            
            
            (35.0
            )%Effective
                tax rate
            
            
            -
            %





F-13





BOND
      LABORATORIES, INC.


(A
      Development Stage Company)


NOTES
      TO
      FINANCIAL STATEMENTS


FOR
      THE
      YEARS ENDED DECEMBER 31, 2006


AND
      FOR
      PERIOD FROM JULY 26, 2005 (INCEPTION) TO DECEMBER 31, 2006





NOTE
      7 -
      INCOME TAXES continued





Deferred
      income taxes result from temporary differences in the recognition of income
      and
      expenses for the financial reporting purposes and for tax purposes. The tax
      effect of these temporary differences representing deferred tax asset and
      liabilities result principally from the following:





December
                31,2006Net
                operating loss carry-forwards
            
            $
            (281,500
            )


The
      Company has a net operating loss carry-forward of approximately $815,000 that
      begin to expire in 2020 available to offset future taxable income.




NOTE
      8 -
      COMMITMENTS AND CONTIGENCIES





The
      Company has entered into various agreements with outside consultants. However,
      certain of these agreements included additional compensation on the basis of
      performance. The consulting agreement are with key shareholders that are
      instrumental to the success of the Company and its development of it
      product.




NOTE
      9 -
      RELATED PARTY





Bond
      is
      currently managed by its majority shareholder who as of December 31, 2006 is
      sole shareholder, officer and director. This shareholder is the sole shareholder
      of Small World Traders.





NOTE
      10 -
      SUBSEQUENT EVENT





Effective
      February 26, 2007, the Company closed the initial phase on its financing. The
      offering consists of the sale of up to 1,000,000 units (“Units”) each unit
      consisting of one share of the Company common stock and one warrant to purchase
      share of the Company common stock at $3.00 per share, at a price of $2.00 per
      Unit.





As
      of
      February 26, 2007, the Company sold over 50% of the offering to forty four
      investors, specifically 527,500 units (consisting of 527,500 shares and 527,500
      warrants to purchase shares of the Company common stock at $3.00 per share)
      for
      an aggregate of $527,500.




F-14




BOND
      LABORATORIES, INC.


(A
      Development Stage Company)


NOTES
      TO
      FINANCIAL STATEMENTS


FOR
      THE
      YEARS ENDED DECEMBER 31, 2006


AND
      FOR
      PERIOD FROM JULY 26, 2005 (INCEPTION) TO DECEMBER 31, 2006





NOTE
      11 -
      CORRECTION OF AN ERROR





The
      Company originally capitalized its intangible assets of its website and company
      logo as an asset to be amortized over their respective lives. Additionally,
      management identified that the Company under accrued interest expense and
      certain advances on the loan from its Related Party. The Company corrected
      these
      errors and expensed those previously capitalized assets as general and
      administrative expenses and accrued additional interest expenses in accordance
      with its respective agreement.




The
      effects of these corrections on the financial statements as they relate to
      each
      line item are as follows:


As
                  Originally
              
              As
              
              Effect
                  ofAssets
              
              Reported
              
              Adjusted
              
              ChangeIntangible
                  assets - net
              
              $
              6,925
              
              $
              -
              
              $
              (6,925
              )Total
                  Assets
              
              $
              42,234
              
              $
              35,309
              
              $
              (6,925
              )LiabilitiesLoans
                  payable-related party
              
              $
              111,868
              
              $
              116,513
              
              $
              4,645Stockholders'
                  EquityAccumulated
                  deficit
              
              $
              (153,735
              )
              $
              (165,304
              )
              $
              (11,569
              )Operating
                  expenses
              
              $
              140,199
              
              $
              151,119
              
              $
              10,920Other
                  expenses
              
              $
              13,537
              
              $
              14,186
              
              $
              649Net
                  loss
              
              $
              153,735
              
              $
              165,304
              
              $
              11,569Net
                  loss per share
              
              $
              (76.87
              )
              $
              (82.65
              )
              $
              (5.78
              )Statement
                  of Cash FlowsNet
                  loss
              
              $
              (153,735
              )
              $
              (165,304
              )
              $
              (11,569
              )Net
                  cash used in operating activities
              
              $
              (69,655
              )
              $
              (81,224
              )
              $
              (11,569
              )Purchase
                  of intangible assets
              
              $
              (6,925
              )
              $
              -
              
              $
              6,925Proceeds
                  from related party loans
              
              $
              111,868
              
              $
              116,513
              
              $
              4,645Net
                  cash provided by financing activities
              
              $
              111,888
              
              $
              116,533
              
              $
              4,645Cash
                  - Beginning of year
              
              $
              -
              
              $
              -
              
              $
              -Cash
                  - End of year
              
              $
              35,309
              
              $
              35,309
              
              $
              -





F-15




**ITEM
      8.**  **CHANGES
      IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
      DISCLOSURE.**




We
      have
      had no disagreements on any matter of accounting principles or practices,
      financial statement disclosure, or auditing scope or procedures with any of
      our
      accountants for the year ended December 31, 2006.




We
      have
      not had any other changes in nor have we had any disagreements, whether or
      not
      resolved, with our accountants on accounting and financial disclosures during
      our two recent fiscal years or any later interim period.





**ITEM
      8A. CONTROLS AND PROCEDURES**





(a)
      Evaluation of Disclosure Controls and Procedures.





Under
      the
      supervision and with the participation of our management, including our Chief
      Executive Officer and Chief Financial Officer, we evaluated the effectiveness
      of
      the design and operation of our disclosure controls and procedures (as such
      term
      is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the
      "Exchange Act")). Disclosure controls and procedures are the controls and
      procedures that we designed to ensure that we record, process, summarize and
      report in a timely manner the information we must disclose in reports that
      we
      file with, or submit to, the Securities and Exchange Commission under the
      Exchange Act. Based on this evaluation, our Chief Executive Officer and our
      Chief Financial Officer concluded that our disclosure controls and procedures
      were effective as of the end of the period covered by this report.





Disclosure
      controls and procedures are controls and procedures that are designed to ensure
      that information required to be disclosed in our reports, filed or submitted
      under the Securities Exchange Act, is recorded, processed, summarized and
      reported, within the time periods specified in the Securities and Exchange
      Commission's rules and forms. Disclosure controls and procedures include,
      without limitation, controls and procedures designed to ensure that information
      required to be disclosed in our reports filed under the Exchange Act are
      accumulated and communicated to management, including our principal executive
      officer and our principal financial officer, as appropriate, to allow timely
      decisions regarding required disclosure.





(b)
      Changes in Internal Control over Financial Reporting.





During
      the year ended December 31, 2006, there was no change in our internal control
      over financial reporting (as such term is defined in Rule 13a-15(f) under the
      Exchange Act) that has materially affected, or is reasonably likely to
      materially affect, our internal control over financial reporting.




**ITEM
      8B. OTHER INFORMATION**





None




11


**PART
      III**





**ITEM
      9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE
      WITH
      SECTION 16(a) OF THE EXCHANGE ACT.**





**Director
      and Executive Officer**





As
      of May
      2005, Mr. Scott Landow accepted the position of Chief Executive Officer and
      sole
      Director of the Company. Mr. Eric Schick serves as the Company’s President.
      Information is set forth below:


Scott
                  Landow
              
              54
              
              Chairman,
                  Chief Executive Officer, and Chief Financial OfficerErick
                  Schick
              
              50
              
              President


The
      chief
      executive officer and sole director and officer of the Company will hold office
      until additional members or officers are duly elected and qualified. The
      background and principal occupations of the sole officer and director of the
      Company is as follows:





**Scott
      D. Landow** is
      our
      sole director, CEO, CFO, and Senior Managing Director of New Business
      Development since May, 2005. From December 2005 through May 2005, Mr. Landow
      was
      President, CEO and a member of the board of directors of Bridgetech Holdings
      International, a publicly traded company leveraging
      significant relationships in China & the U.S. to capitalize on proprietary
      opportunities in high growth segments of the healthcare industry. From
      August 2000 through February 2005, Mr. Landow was President of Parentech Inc.,
      an emerging medical device company for newborns and infants.





**Eric
      Schick** ,
      is our
      President who joined the company and Board of Directors in December 2006. Prior
      to joining Bond, Mr. Schick was Vice President and National Sales Manager for
      Natrol, an $80 million nutritional supplements company. From 2004 to 2005 he
      was
      Vice President and Chief Sales officer of Ideashpere, manufacturer of Twin
      labs
      vitamins, minerals, and nutritional supplements, Nature’s Herb and Alvita Teas
      for the health food industry, and was responsible for overseeing $120 million
      in
      annual sales. He began his career in the Nutraceutical business at Lenier Health
      Products where he spent 20 years with a majority of his time heading sales
      as
      Executive Vice President of sales and merchandising and a member of the
      executive management group. At Lenier, Mr. Schick assumed P & L
      responsibility of $700 million, took direct responsibility for sales and
      merchandising, and cross functional responsibility for operations, customer
      service, and product development teams





COMPLIANCE
      WITH SECTION 16(a) OF THE EXCHANGE ACT 9.A. DIRECTORS AND EXECUTIVE OFFICERS,
      PROMOTERS, AND CONTROL PERSONS:





The
      Company is aware that all filings of Form 4 and 5 required of Section 16(a)
      of
      the Exchange Act of Directors, Officers or holders of 10% of the Company's
      shares have not been timely and the Company has instituted procedures to ensure
      compliance in the future.





**ITEM
      10. EXECUTIVE COMPENSATION**





*General.* Mr.
      Scott
      Landow serves as the Company’s sole-director and chief executive officer.
      Pursuant to a Management Services Agreement, executed and approved by the
      Company, Mr. Landow was compensated approximately $120,000 for management fees
      and $6,000 for fringe benefits. Other sources or forms of compensation were
      not
      paid or collected for Fiscal year ended 2006.




12





Mr.
      Eric
      Schick serves as the Company’s President. Mr. Schick will be compensated
      approximately $120,000 for management fees.





**Summary
      Compensation Table**




The
      following table sets forth for the year ended December 31, 2006 and 2005
      compensation awarded to, paid to, or earned by, Mr.
      Scott  Landow,  our
      sole
      Director and Chief Executive Officer ,
      and  our
      three
      other most highly compensated executive officers whose total compensation during
      the last fiscal year exceeded $100,000, if any.




**Long
                Term Compensation****Annual
                Compensation**
            
            **Awards**
            
            **Payouts****Name
                and Principal Position**
            
            **Year**
            
            **Salary**
            
            **Bonus**
            
            **Other
                Annual**
              **Compensation**
            
            **Restricted Stock**
              **Award
                (s)**
            
            **Securities**
              **Underlying**
              **Options/SARs
                (#)**
            
            **LTIP**
              **Payouts**
            
            **All Other**
              **Compen-**
              **sation**Scott
                Landow
              CEO,
                CFO and sole Director
            
            
            2006
            
            $
            120,000
            )
            
            
            
            $
            —
            
            
            —
            
            
            —
            
            
            —
            
            
            —2005
            
            $
            80,000
            )
            
            
            
            $
            —
            
            
            —
            
            
            —
            
            
            —
            
            
            —Eric
                Schick, President
            
            
            2007
            
            
            120,000
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            $




**Employment
      Agreements**




**Aggregated
      Option Exercises and Fiscal Year-End Option Value Table**




**Name**
            
            **Shares**
              **Acquired on**
              **Exercise**
            
            **Value**
              **Realized**
            
            **Number of Securities**
              **Underlying**
              **Unexercised**
              **Options/SAR at**
              **December 31, 2005**
              **Exercisable/**
              **Unexercisable**
            
            **Value
                of**
              **Unexercised**
              **In-the-money**
              **Options/SAR at**
              **December 31, 2005**
              **Exercisable/**
              **Unexercisable**Scott
                Landow,
              CEO,
                CFO and sole Director
            
            
            0
            
            $
            0Eric
                Schick, President
            
            
            0
            
            $
            00
            
            $
            0




**Compensation
      of BOD Member**




We
      currently have one director. Our current compensation policy for directors
      is to compensate them through options to purchase common stock as consideration
      for their joining our board and/or providing continued services as a director.
      We do not currently provide our directors with cash compensation, although
      we do
      reimburse their expenses, with exception for a chairman of the board. No
      additional amounts are payable to the Company’s directors for committee
      participation or special assignments. There are no other arrangements pursuant
      to which any directors was compensated during the Company’s last completed
      fiscal year for any service provided.




13




**ITEM
      11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND RELATED STOCKHOLDER
      MATTERS.**




The
      following table sets forth certain information regarding beneficial ownership
      of
      the common stock as of December 31, 2005 and August 14, 2006, by
      (i) each person who is known by the Company to beneficially own more than
      5% of the any of the outstanding classes of Stock, (ii) each director of
      the Company, (iii) each of the Chief Executive Officers and the two
      (2) most highly compensated executive officers who earned in excess of
      $100,000 for all services in all capacities (collectively, the “Named Executive
      Officers”) and (iv) all directors and executive officers of the Company as
      a group.




The
      number and percentage of shares beneficially owned is determined in accordance
      with Rule 13d-3 and 13d-5 of the Exchange Act, and the information is not
      necessarily indicative of beneficial ownership for any other purpose and is
      based on 5,002,000 shares beneficially owned as of December 31, 2006. We believe
      that each individual or entity named has sole investment and voting power with
      respect to the securities indicated as beneficially owned by them, subject
      to
      community property laws, where applicable, except where otherwise noted. Unless
      otherwise stated, the address of each person; 777 S. Highway 101, Suite 215,
      Solana Beach, CA 92075.





**Name
                of Beneficial Owner**
            
            **Number of Shares**
              **of Common Stock****(1)**
            
            **Percent of**
              **Class****(1)**Scott
                Landow (1)
            
            
            1,250,000
            
            
            25
            %Small
                World Traders, Inc. (1)
            
            
            1,275,000
            
            
            25
            %Landow
                Revocable Trust 2006 (1)
            
            
            1,250,000
            
            
            25
            %




(1)
                Scott Landow, through Landow Revocable Trust 2006 which is controlled
                by
                Scott Landow , controls Small World Traders, Inc.




**Changes
      in Control**




We
      are
      not aware of any arrangements that may result in a change in control of the
      Company.




**DESCRIPTION
      OF SECURITIES**




**General**




Our
      authorized capital stock consists of 75,000,000 shares of common stock, par
      value $ .01, and 10,000,000 shares of preferred stock.




14




**Common
      Stock**




The
      shares of our common stock presently outstanding, and any shares of our common
      stock issued upon exercise of stock options and/or warrants, will be fully
      paid
      and non-assessable. Each holder of common stock is entitled to one vote for
      each
      share owned on all matters voted upon by shareholders, and a majority vote
      is
      required for all actions to be taken by shareholders. In the event we liquidate,
      dissolve or wind-up our operations, the holders of the common stock are entitled
      to share equally and ratably in our assets, if any, remaining after the payment
      of all our debts and liabilities and the liquidation preference of any shares
      of
      preferred stock that may then be outstanding. The common stock has no preemptive
      rights, no cumulative voting rights, and no redemption, sinking fund, or
      conversion provisions. Since the holders of common stock do not have cumulative
      voting rights, holders of more than 50% of the outstanding shares can elect
      all
      of our Directors, and the holders of the remaining shares by themselves cannot
      elect any Directors. Holders of common stock are entitled to receive dividends,
      if and when declared by the Board of Directors, out of funds legally available
      for such purpose, subject to the dividend and liquidation rights of any
      preferred stock that may then be outstanding.




**Preferred
      Stock**




We
      are
      authorized to issue 10,000,000 shares of preferred stock, $.01 par value, of
      which 5,000,000 are issued and outstanding as of August 31, 2006.




**Dividend
      Policy**




We
      have
      never declared or paid any cash dividends on our common stock. We currently
      intend to retain future earnings, if any, to finance the expansion of our
      business. As a result, we do not anticipate paying any cash dividends in the
      foreseeable future.





**Options
      and Warrants:**




As
      of
      December 31, 2006 there were no options or warrants to acquire shares of the
      Company’s outstanding common stock. The Company will be issuing warrants in the
      offering.




**Convertible
      Securities**





At
      December 31, 2006, the Company issued $430,000 in two year secured convertible
      notes, convertible into shares of the Company’s common stock at $1.00 per
      share.




**Amendment
      of our Bylaws**




Our
      bylaws may be adopted, amended or repealed by the affirmative vote of a majority
      of our outstanding shares. Subject to applicable law, our bylaws also may be
      adopted, amended or repealed by our board of directors.





**Transfer
      Agent**





On
      August
      31, 2006, the Company engaged Colonial Transfer Agent to serve in the capacity
      of transfer agent. Their mailing address and telephone number Colonial Stock
      Transfer, 66 Exchange Place, Salt Lake City, UT 84111 - Phone is (801)
      355-5740.




15





**ITEM
      12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
      INDPENDENCE.**




Loan
      and Advances from Officers & Stockholders




During
      the period May 1, 2005(inception) though December 31, 2006, certain officers
      and
      stockholders advanced to the Company.




**Name**
            
            **Position**
            
            **Cash**
              **Advances**
            
            **Salary
                Deferred**
            
            **Amount**
              **Outstanding**
              **at**
              **December
                31,**
              **2006**Small
                World Traders, Inc.
            
            
            Scott
                Landow, through Landow Revocable Trust 2006 which is controlled by
                Scott
                Landow, controls Small World Traders, Inc.
            
            $
            99,247.92
            
            
            
            
            $
            99,247.92Scott
                Landow
            
            
            Director,
                CEO, CFO
            
            
            
            
            $
            200,000
            
            $
            200,000




**ITEM
      13. EXHIBITS**




**Exhibits**


3.1
              
              Articles
                  of Incorporation (1)3.2
              
              Amendments
                  to Articles of Incorporation (1)3.3
              
              Bylaws
                  of the Corporation (1)10.1
              
              Employment
                  Agreement Scott Landow (1)10.2
              
              Securities
                  Purchase Agreement (1)31.1
              
              Certification
                  of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley
                  Act.(2)31.2
              
              Certification
                  of Principal Financial and Accounting Officer Pursuant to Section
                  302 of
                  the Sarbanes-Oxley Act.(2)32.1
              
              Certification
                  of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley
                  Act.(2)32.2
              
              Certification
                  of Chief Accounting Officer Pursuant to Section 906 of the Sarbanes-Oxley
                  Act.(2)





(1).
      Incorporated by reference to the same exhibit filed with Amendment No. 3 to
      the
      Company’s Registration Statement on Form SB2 (Commission File No.
      333-137170).




(2)
      Filed
      herein.




16





**ITEM
      14. PRINCIPLE ACCOUNTANT FEES AND SERVICES**





**Audit
      Fees.** The
      aggregate fees billed by Jewett, Schwartz, Wolfe & Associates **** for
      professional services rendered for the audit of the Company’s annual financial
      statements for the fiscal years ended December 31, 2005 approximated $12,000.





**Audit-Related
      Fees.** The
      aggregate fees billed by **** Jewett,
      Schwartz, Wolfe & Associates **** for
      assurance and related services that are reasonably related to the performance
      of
      the audit or review of the Company’s financial statements for the fiscal year
      ended December 31 2005 and 2006, and that are not disclosed in the paragraph
      captioned “Audit Fees” above, were $0 and $0, respectively.





**Tax
      Fees.** The
      aggregate fees billed by Jewett, Schwartz, Wolfe & Associates for
      professional services rendered for tax compliance, tax advice and tax planning
      for the fiscal year ended December 31, 2005 and 2006 were $0.





**All
      Other Fees.** The
      aggregate fees billed by Jewett, Schwartz, Wolfe & Associates **** for
      products and services, other than the services described in the paragraphs
      “Audit Fees,” “Audit-Related Fees,” and “Tax Fees” above for the fiscal years
      ended December 31, 2005 and 2006 were $0 and $0, respectively.





**ITEM
      15. SIGNATURES.**





In
      accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934,
      the
      Registrant has duly caused this report to be signed on its behalf by the
      undersigned, there unto duly authorized.





BOND
      LABORATORIES, INC.




By /s/
      Scott
      Landow





Scott
      Landow


Chairman,
      CEO


(Sole
      executive officer of the registrant)


April
      2,
      2007





By /s/
      Scott
      Landow





Scott
      Landow


Chief
      Financial officer


April
      2,
      2007





In
      accordance with the requirements of the Exchange Act, this report has been
      signed by the following persons on behalf of the registrant and in the
      capacities and on the dates indicated:








Signatures
            
            Title
            
            DateScott
              Landow
            
            CEO/CFO/Director
            
            April 2,
              2007





17